<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="151">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 22, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02607813</url>
  </required_header>
  <id_info>
    <org_study_id>CLXH254X2101</org_study_id>
    <secondary_id>2015-003421-33</secondary_id>
    <nct_id>NCT02607813</nct_id>
  </id_info>
  <brief_title>Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations</brief_title>
  <official_title>A Phase I Dose Finding Study of Oral LXH254 in Adult Patients With Advanced Solid Tumors Harboring MAPK Pathway Alterations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Germany: BfArM (The Federal Institute for Drugs and Medical Devices)</authority>
    <authority>Netherlands: Dutch Health Care Inspectorate</authority>
    <authority>Spain: Agencia Espanola del Medicamiento y Productos Sanitarios</authority>
    <authority>France: Agence Nationale de sécurité du Médicament et des Produits de Santé (ANSM)</authority>
    <authority>Korea: Korea Food and Drug Administration (KFDA)</authority>
    <authority>Japan: Pharmaceuticals and Medical Devices Agency (PMDA)</authority>
    <authority>Canada: Health Canada</authority>
    <authority>Switzerland: Swissmedic</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase I Study of LXH254 in Patients With Advanced Solid Tumors That Harbor MAPK Pathway
      Alterations
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Safety and tolerability as assessed by incidence and severity of adverse events (AEs), dose interruptions, reductions, and dose intensity.</measure>
    <time_frame>From Cycle 1 Day 1 until 30 days post study treatment (expected duration approximately 12 months)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>cycle = 28 days</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and nature of dose limiting toxicities (DLTs) (dose escalation only)</measure>
    <time_frame>28 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>cycle = 28 days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>Every 2 cycles after starting LXH254 treatment until end of treatment; expected duration approximately 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>cycle = 28 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>Every 2 cycles after starting LXH254 treatment until end of treatment; expected duration approximately 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>cycle = 28 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DoR)</measure>
    <time_frame>Every 2 cycles after starting LXH254 treatment until end of treatment; expected duration approximately 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>cycle = 28 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Every 2 cycles after starting LXH254 treatment until disease progression; expected duration approximately 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>cycle = 28 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS) - only for dose expansion</measure>
    <time_frame>From time of start treatment until the date of death; expected duration approximately 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>cycle = 28 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of LXH254</measure>
    <time_frame>Cycle 1 days 1, 2, 3, 8, 15, and 16; Cycle 2 days 1 and 15; Cycle 3 Day 1; Cycle 5 Day 1</time_frame>
    <safety_issue>No</safety_issue>
    <description>cycle = 28 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Derived PK parameters of LXH254: Area Under the Curve (AUC)</measure>
    <time_frame>Cycle 1 days 1, 2, 3, 8, 15, and 16; Cycle 2 days 1 and 15; Cycle 3 Day 1; Cycle 5 Day 1</time_frame>
    <safety_issue>No</safety_issue>
    <description>cycle = 28 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Derived PK parameters of LXH254: Peak Plasma Concentration (Cmax)</measure>
    <time_frame>Cycle 1 days 1, 2, 3, 8, 15, and 16; Cycle 2 days 1 and 15; Cycle 3 Day 1; Cycle 5 Day 1</time_frame>
    <safety_issue>No</safety_issue>
    <description>cycle = 28 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Derived PK parameters of LXH254: Time to Peak Plasma Concentration (Tmax)</measure>
    <time_frame>Cycle 1 days 1, 2, 3, 8, 15, and 16; Cycle 2 days 1 and 15; Cycle 3 Day 1; Cycle 5 Day 1</time_frame>
    <safety_issue>No</safety_issue>
    <description>cycle = 28 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Derived PK parameters of LXH254: half-life (T1/2)</measure>
    <time_frame>Cycle 1 days 1, 2, 3, 8, 15, and 16; Cycle 2 days 1 and 15; Cycle 3 Day 1; Cycle 5 Day 1</time_frame>
    <safety_issue>No</safety_issue>
    <description>cycle = 28 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline of pharmacodynamics (PD) marker DUSP6 in tumor tissue and in blood</measure>
    <time_frame>Cycle 1 day 1, 2, 3, 15, and 16; upon disease progression (expected duration approximately 12 months)</time_frame>
    <safety_issue>No</safety_issue>
    <description>cycle = 28 days</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">81</enrollment>
  <condition>NSCLC</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Melanoma</condition>
  <condition>Other Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Dose escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose expansion: Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose expansion: Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose expansion: Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LXH254</intervention_name>
    <description>pan-RAF inhibitor</description>
    <arm_group_label>Dose escalation</arm_group_label>
    <arm_group_label>Dose expansion: Group 1</arm_group_label>
    <arm_group_label>Dose expansion: Group 2</arm_group_label>
    <arm_group_label>Dose expansion: Group 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients participating in this clinical trial must have progressed following
             standard therapy, or for whom, in the opinion of the Investigator, no effective
             standard therapy exists, is tolerated or appropriate.

          -  Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1

          -  Presence of at least one measurable lesion according to RECIST v1.1.

          -  Documented MAPK alteration

        Exclusion Criteria:

        - Prior treatment with a BRAFi, MEKi and/or pan-RAF inihibitors for patients to be
        enrolled in group 1 and 2 in the dose expansion part.

        Exceptions may be made after documented agreement between Novartis and Investigator.

          -  History or current evidence of retinal vein occlusion (RVO) or current risk factors
             for RVO.

          -  Any medical condition that would, in the investigator's judgment, prevent the
             patient's participation in the clinical study due to safety concerns or compliance
             with clinical study procedures.

          -  Patients receiving proton pump inhibitors which cannot be discontinued 3 days prior
             to the start study treatment and for the duration of the study.

          -  Pregnant or nursing (lactating) women

        Other inclusion/exclusion criteria as per protocol may apply.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center SC - LXH254X2101</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thrusha Chauhan</last_name>
      <email>chauhant@mskcc.org</email>
    </contact>
    <investigator>
      <last_name>Gopakumar Iyer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UT M.D Anderson Cancer Center SC - LXH254X2101</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cymone McNeil</last_name>
      <email>cvmcneil@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Filip Janku</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M6G 1Z6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>Japan</country>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>France</country>
    <country>Korea, Republic of</country>
    <country>Spain</country>
    <country>Switzerland</country>
  </removed_countries>
  <verification_date>May 2016</verification_date>
  <lastchanged_date>May 26, 2016</lastchanged_date>
  <firstreceived_date>November 5, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>LXH254, CRAF, MAPK, solid tumor</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
